Generic Travatan Z Availability

Travatan Z is a brand name of travoprost ophthalmic, approved by the FDA in the following formulation(s):

TRAVATAN Z (travoprost - solution/drops;ophthalmic)

  • Manufacturer: ALCON PHARMS LTD
    Approval date: September 21, 2006
    Strength(s): 0.004% [RLD]

Has a generic version of Travatan Z been approved?

No. There is currently no therapeutically equivalent version of Travatan Z available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Travatan Z. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
    Patent 5,510,383
    Issued: April 23, 1996
    Inventor(s): Bishop; John E. & DeSantis, Jr.; Louis & Sallee; Verney L.
    Assignee(s): Alcon Laboratories, Inc.
    Disclosed is the use of cloprostenol, fluprostenol, and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
    Patent expiration dates:
    • August 3, 2013
      ✓ 
      Patent use: METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
      ✓ 
      Drug product
  • Use of cloprostenol and fluprostenol analogues to treat glaucoma and ocular hypertension
    Patent 5,889,052
    Issued: March 30, 1999
    Inventor(s): Klimko; Peter G. & Bishop; John E. & Sallee; Verney L. & Zinke; Paul W.
    Assignee(s): Alcon Laboraties, Inc.
    Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
    Patent expiration dates:
    • December 2, 2014
      ✓ 
      Patent use: METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
      ✓ 
      Drug product
  • Self preserved aqueous pharmaceutical compositions
    Patent 8,268,299
    Issued: September 18, 2012
    Inventor(s): Kabra; Bhagwati P. & Chowhan; Masood A. & Schneider; L. Wayne & Han; Wesley Wehsin
    Assignee(s): Alcon Research, Ltd.
    The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borat or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.
    Patent expiration dates:
    • October 13, 2029
      ✓ 
      Drug product
  • Self-preserved aqueous pharmaceutical compositions
    Patent 8,323,630
    Issued: December 4, 2012
    Inventor(s): Kabra; Bhagwati P. & Chowhan; Masood A. & Schneider; L. Wayne & Han; Wesley Wehsin
    Assignee(s): Alcon Research, Ltd.
    The present invention is directed to the provision of multi-dose, self-preserved ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP), without requiring the presence of conventional anti-microbial preservative agents, such as benzalkonium chloride. The compositions are effectively preserved by a balanced ionic buffer system containing zinc ions at a concentration of 0.04 to 0.9 mM, preferably 0.04 to 0.4 mM. One aspect of the balanced buffer system is limitation of the amount of buffering anions present to a concentration of 15 mM or less, preferably 5 mM or less. In a preferred embodiment, the compositions also contain borate or, most preferably, one or more borate/polyol complexes. The use of propylene glycol as the polyol in such complexes is strongly preferred. Limiting the amount of divalent metals other than zinc and the amount of ionized salts present has also been determined to be important to maximize the antimicrobial activity of the balanced buffer systems.
    Patent expiration dates:
    • September 20, 2027
      ✓ 
      Drug product
  • Self preserved aqueous pharmaceutical compositions
    Patent 8,388,941
    Issued: March 5, 2013
    Assignee(s): Alcon Research, Ltd.
    The use of a borate/polyol and zinc system to enhance the antimicrobial activity of multi-dose pharmaceutical compositions is described. The compositions do not require a conventional anti-microbial preservative and therefore are referred to as being ‘self-preserved’. The compositions possess sufficient antimicrobial activity to satisfy the preservative efficacy requirements of the USP for aqueous ophthalmic compositions.
    Patent expiration dates:
    • September 20, 2027
      ✓ 
      Drug product

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web4)